Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...

Vertex lost a legal battle against the federal government on Monday over its proposed fertility support program that would have offered up to $70,000 in services for certain gene therapy patients.